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The introduction of disease-modifying therapies (DMTs) for multiple sclerosis (MS) has been 
associated with little measurable improvement in long-term disability he introduction of disease-
modifying therapies (DMTs) for multiple sclerosis (MS) has been associated with little measurable 
improvement in long-term disability outcomes.1-5 The reasons for the limited quantifiable impact of 
these drugs on long-term disability are likely to relate in part to the rapid evolution of the 
therapeutic landscape in MS and a lack of detailed, prospective population-based disability data with 
follow-up durations sufficient to capture long-term out-comes. However, it may also be that current 
treatment strategies are not optimized to deliver the best possible long-term outcomes. Permanent 
disability in MS is thought to occur through a number of mechanisms including the sequelae of 
relapses, the insidious effects of subclinical inflammation, and neurodegeneration. Current DMTs are 
primarily directed at the inflammatory phase of disease. The modest impact of MS DMTs on long-
term disability has led to speculation that the neurodegenerative phase of MS may represent a 
separate, parallel pathology. However, DMTs have been most effective when aggressive treatments 
have been applied very early in the clinical course of MS.6,7 It is possible that an early window of 
therapeutic opportunity exists in which the biology of disease can be modified for longer-term 
benefit8; however, after a certain period, a threshold is crossed beyond which cumulative immune-
mediated injury leads to sustained and progressive neurological disability. 
Disease-modifying therapies in MS can be broadly divided according to the efficacy with which they 
prevent MS relapses. The licensed DMTs with the highest efficacy are associated with more complex 
safety profiles, monitoring requirements, and the need for hospital or day unit admission. These 
factors tend to lead clinicians or treatment guidelines to recommend that they be reserved for use in 
individuals with the most aggressive or resistant forms of MS.9 In those with moderately active MS, 
clinicians often adopt an escalation approach whereby a DMT is selected that is considered to be 
most safe, subsequently escalating to more efficacious therapies, with more complex safety profiles, 
in the event of continued disease activity. However, in light of current knowledge, it is possible that 
the inevitable delay imposed by escalation strategies may result in a lost therapeutic opportunity. 
Several consensus working groups in MS9-11 have highlighted the need for further research to 
establish optimum treatment and monitoring strategies in MS. In this study, we report long-term, 
real-life clinical outcomes in a large, well-characterized cohort of patients with MS, according to 
whether they were treated initially with high-efficacy or moderate-efficacyDMT (with subsequent 
escalation if indicated). 
Methods 
Patients and Data Collection 
This study was undertaken on a population-based cohort of patients with MS in southeast Wales, 
United Kingdom, which has a total population of 1.4 million from the cities of Cardiff and Newport 
and the surrounding communities. Data collection for this population has been conducted by means 
of a cross-sectional epidemiological study in 1985,12 with periodic updates thereafter.13,14 Since 
1999, longitudinal data have been gathered prospectively on this population and is estimated to 
have captured more than 97% of the MS cases in this region15 with a total of more than 3000 
patients. At each encounter, data are gathered including relapse history and DMT prescription. 
Patients undergo a comprehensive clinical assessment at least annually. Disability is measured using 
the Expanded Disability Status Scale (EDSS).16 
Data storage is within a secure National Health Service–hosted web-based departmental database, 
registered under the Data Protection Act. Written consent was obtained from all patients. The study 
is approved by the South East Wales Re-search Ethics Committee (ref No.05/WSE03/111). 
Inclusion and Exclusion Criteria 
All patients who had ever been prescribed a licensed DMT for MS while living within the region and 
who had comprehensive long-term follow-up data were included. Patients in whom a DMT had been 
commenced outside of area, with insufficient data, or who were part of an externally sponsored 
clinical trial were excluded. 
Disease-modifying therapies were classified as follows: monoclonal antibodies (alemtuzumab and 
natalizumab) were categorized as high efficacy and all other DMTs, as moderate efficacy 
(interferons, glatiramer acetate, dimethyl fumarate, fingolimod, and teriflunomide).9 Patients’ initial 
treatment strategy was classified according to whether their first-line treatment was high efficacy 
(early intensive treatment [EIT] group) or moderate efficacy (escalation [ESC] group). Individuals who 
received EIT were selected on the basis of poor prognostic factors including higher relapse rates and 
radiological evidence of recent MS activity. Those individuals who embarked on an ESC strategy with 
a first-line moderate efficacy DMT had regular clinical and radiological monitoring and could escalate 
to a high-efficacy agent if required. 
Prospectively recorded data on dates of starting and stopping DMTs (if not current) were used for 
analysis. Treatment discontinuation was defined as a period of treatment of 90 days or more.17 
Where the same DMT was restarted within 90days of discontinuation, prescriptions were 
amalgamated. Alemtuzumab was an exception since a standard regimen consists of 2 short courses 
1 year apart and no further treatment if patients remain clinically and radiologically stable. 
Indication and reasons for discontinuation of DMTs were analyzed, noting that more than 1 
discontinuation reason may be classified per event. Systematic review of clinical records of all 
individuals was performed to validate the data set. Data capture began in January 1998 and ended in 
December 2016. Analysis began in January 2017. 
 
 
Statistical Analysis 
After patient classification, demographic details were compared between EIT and ESC groups using t 
test or Mann-Whitney U test (if data were not normally distributed) and χ2 test for categori-
caldata.Annualizedrelapseratesbeforeandaftertreatmentwere compared using Mann-Whitney U 
test. Significance was set at P = .05. 
Primary outcome was change in EDSS score at 5 years. Base-line EDSS score was defined as that 
closest to starting DMT, and final EDSS score was measured 5 years later (both ±1 year). The change 
in EDSS score from baseline to 5-year follow-up was compared between EIT and ESC groups using a 
linear regression model. The secondary outcome was sustained accumulation of disability (SAD), 
defined as an increase in EDSS score of 1.5 if baseline was 0, an increase of 1.0 if baseline was 1.0 to 
5.5, or an increase of 0.5 if baseline was 5.5 or higher, sustained for at least 6 months.18 Cox 
proportional hazards regression modeling was used to compare the hazard of SAD in the EIT and ESC 
groups. All models were performed both with-out any adjustment for confounders and also adjusted 
a priori for known confounders of outcome: sex and age at first starting DMT and calendar year of 
starting DMT (to address whether secular trends in treatment may have affected the results given 
the long standby period). For the adjusted models, backward stepwise regression was used to 
generate a final model containing only treatment strategy and covariates that significantly 
contributed to the model. Escalation to a high-efficacy DMT for those in the ESC group was included 
in the linear regression model for change in EDSS score as a binary variable and in the Cox 
proportional hazards regression model for hazard of SAD as a time-dependent variable. 
Two sensitivity analyses were performed. First, we recognize that dichotomizing treatments into 2 
levels of efficacy is somewhat arbitrary but is not without precedent.9 In recognition of the fact that 
a switch from injectables to fingolimod might be regarded as escalation, we classified fingolimod as a 
high-efficacy treatment and analyzed the data accordingly. Second, an analysis including only those 
patients treated since 2005 was performed; this is the date from which high-efficacy treatment was 
freely available in Cardiff, so that a choice between high- and moderate-efficacyDMTat disease onset 
or diagnosis was always possible. Prior to that date, patients received high-efficacy treatment mainly 
by referral to another specialist center. 
Results 
At the time of data extraction, there were 2568 registered patients with MS with complete clinical 
data from disease on-set. Of 720 patients prescribed a DMT before January 2017, 109 (15.1%) were 
excluded from the analysis (45 had insufficient clinical data, 25 were treated in a clinical trial, 38 
were first treated out of area, and 1 was treated via private prescription), leaving 592 (23.1% of the 
total cohort and 82% of those prescribed a DMT) eligible for inclusion in the current analysis. Of 592 
patients, 104 (17.6%) had been prescribed a high-efficacy DMT as first-line (EIT), while 488 patients 
(82.4%) had commenced DMT with a moderate-efficacy agent (ESC). Individuals who received EIT 
were most likely to receive alemtuzumab than natalizumab (70 [67%] vs 34 [33%]), while individuals 
who received high-efficacy therapy second line (as part of an escalation algorithm) were most likely 
to receive natalizumab than alemtuzumab (43 [74%] vs 15 [26%]). 
Of 488 patients who initially embarked on moderate-efficacy treatment, 58 patients (11.9%) 
subsequently went on to receive a high-efficacy DMT (Figure 1). The reason for escalation was 
clinical disease activity (relapses) in 52 cases, sub-clinical radiological evidence of disease activity in 5 
cases, and 1 case had no evidence of clinical or radiological evidence of disease activity during the 12 
months before escalation. 
Median time spent on any single disease-modifying drug was 2.0 years (95% CI, 1.8-2.4). In those 
patients from the ESC group who later escalated to a high-efficacy DMT, the median time to 
escalation was 2.4 years (95% CI, 2.1-3.5). Sixty-one individuals received fingolimod in the overall 
cohort, and in the sensitivity analysis were reclassified to EIT (n = 2) and escalation from moderate- 
to high-efficacy DMT (n = 59). 
 
Comparison of Treatment Strategies 
Demographics and Relapse Rates 
The baseline characteristics of all patients in the 2 groups are shown in Table 1. There was no 
difference in the sex ratio (EIT 1:3.2; ESC 1:2.5; P = .37), mean (SD) age at symptom onset (EIT: 29.8 
[9.2] years; ESC: 30.3 [9.4] years;P = .73), median (IQR) base-line EDSS score (EIT: 3.5 [2.0-5.0]; ESC: 
3.5 [2.0-5.0]; P = .55), or median (SD) follow-up time (EIT: 5.8 [3.6] years; ESC: 6.9 [5.3] years; P = .30) 
between the EIT and ESC groups. As expected, the pretreatment annualized relapse rate (ARR) was 
higher in the EIT group (1.7; interquartile range [IQR], 0.9-2.8) than the ESC group (0.7; IQR, 0.4-1.3; 
P < .001). In retrospect, those who commenced a moderate-efficacy DMT but subsequently 
escalated to a high-efficacy agent had a pretreatment ARR of 1.2 (IQR, 0.7-2.1) compared with 0.7 
(IQR, 0.4-1.2) in those who continued with moderate-efficacy DMT (P < .001). 
The ARR fell in all groups following the introduction of a DMT (Table 1). Following DMT, the ARR was 
0.16 (IQR, 0-0.5) in the ESC group and 0 (IQR, 0-0.3) in the EIT group (P = .02). Within the ESC group, 
the ARR following initial DMT was 0.9 (IQR, 0.7-1.5) in those patients who later escalated to high-
efficacy treatment, and ARR was 0 (IQR, 0-0.2) in that group following escalation to high-efficacy 
DMT. The ARR was 0.11 (IQR, 0-0.4) in the group who continued with moderate-efficacy DMTs (P = 
.01). 
Change in EDSS Score Over 5 Years 
Overall, 179 patients (41 in the EIT group and 138 in the ESC group) had EDSS scores available at 
baseline and at 5-year follow-up. The mean (SD) baseline EDSS score was 4.2 (1.7) for those in the 
EIT group and 3.5 (1.7) in the ESC group. Similarly, in those patients with both baseline and 5-year 
EDSS scores available, median (IQR) baseline EDSS was 4.5 (3.0-5.5) in the EIT group and 3.5 (2.0-4.5) 
in the ESC group. Mean change in EDSS score at 5 years was +0.3 in the EIT group, and +1.2 in the 
ESC group (β = −0.92; 95% CI, −1.45 to −0.41; P < .001). After adjustment for relevant covariates, the 
EIT group had a significantly lower change in EDSS score at 5 years compared with the ESC group (β = 
−0.85; 95% CI, −1.38 to -0.32; P = .002). The only additional covariate to be retained in the final 
model was age at first DMT treatment (β = 0.03; 95% CI, 0.002-0.05; P = .03). The unadjusted and 
final adjusted linear regression models are shown in Table 2. There was no change in this finding for 
either of the sensitivity analyses (data not shown). 
 
Sustained Accumulation of Disability 
In the total cohort, median time to SAD was 6.0 years (95% CI, 3.4-8.2) for the EIT group, and 3.1 
(95% CI, 2.8-4.0) for the ESC group (log-rank test P = .05). For those within the ESC group who 
escalated to high-efficacy DMT as second-line treatment, median time to SAD was 3.3 years (95% CI, 
1.8-5.6; compared with EIT group log-rank test P = .08), and 60% of this group reached SAD while on 
initial moderate-efficacy treatment be-fore escalation of treatment. For those who continued with 
moderate-efficacy DMT, median time to SAD was 3.1 years (95% CI, 2.6-4.0; compared with EIT 
group log-rank test P = .07). Treatment strategy was not associated with hazard of SAD either 
analyzed alone (hazard ratio, 0.72; 95% CI, 0.52-1.01; P = .05) or after adjustment for relevant 
covariates (hazard ratio, 0.74; 95% CI, 0.52-1.06; P =.10)(Figure 2). Neither unadjusted nor adjusted 
model violated the proportional hazards assumption. The results of the Cox proportional hazards 
regression models are shown in Table 3. Again, results were unchanged in both sensitivity analyses 
(data not shown). 
 
Safety 
Adverse event data on patients receiving alemtuzumab within this cohort has been published 
previously (n = 100)19: 87% developed infusion-related adverse events, and 47% developed 
autoimmunity (35 thyroid, 3 immune thrombocytopenic purpura, and 13 other), but there were no 
serious infections and no treatment-related deaths. In patients receiving natalizumab, there were no 
serious adverse events, no cases of progressive multifocal leukoencephalopathy, and no treatment-
related deaths. In patients receiving moderate-efficacy DMTs, there were no treatment-related 
deaths but 7 serious adverse events (1.4%): 3 cases of necrotic skin reactions, 1 case of anaphylaxis 
while receiving injectable DMTs, and 3 severe infections while receiving fingolimod. 
 
 
Discussion 
The concept of escalation vs early intensive treatment strategies has arisen largely as a result of 
concerns over the complex safety profiles of the high-efficacy DMTs. Contemporary treatment 
algorithms often suggest reserving first-line high-efficacy treatments for individuals considered at 
highest risk of accumulating disability, usually those who meet an arbitrarily high level of clinical or 
radiological MS activity. For an escalation approach to be successful in the remaining cases, it is 
necessary that adequate procedure is in place to detect and respond to “failure” of first-line 
moderate-efficacy DMTs with-out the individual accumulating permanent disability in the interim 
and that any delay does not diminish the efficacy of subsequent DMTs. These assumptions have not 
been tested in a randomized clinical trial. The benefit of reserving high-efficacy interventions for 
those patients perceived to have the most active disease therefore remains unclear. 
In this study, we compared long-term outcomes in patients who started receiving EIT with a high-
efficacy DMTvs those who commenced receiving an ESC strategy. We found that although patients 
were selected to receive EIT on the basis of poor prognostic factors including more active disease, it 
was this patient group that had better long-term outcomes. In patients who started to receive an 
ESC treatment strategy, there was a mean increase in EDSS score of 1.2 over 5 years despite clinical 
surveillance and targeted escalation, compared with only 0.3 in the EIT group. Time to SAD appeared 
delayed in those receiving EIT (6.0 years) compared with those who had an escalation approach (3.1 
years), but the hazard of reaching SAD did not remain statistically significant after adjustment for 
potential confounders. Interestingly, age at first DMT was the only variable identified to be as-
sociated with hazard of SAD, whereas in the analysis of 5-year change in EDSS score, the effect size 
of initial treatment strategy was much greater than that of age at first DMT. This discrepancy may be 
explained by the observation that in early MS, SAD ap-pearstobedrivenbyrelapseactivity,20 
whereas5-yearEDSSscore may better capture the longer-term neurodegenerative component of 
disability. Our results therefore support the premise that DMT efficacy on relapse activity is largely 
age dependent21 but raise the possibility that the effect of DMT may be greater than the effect of 
age on the evolution of longer-term disability. 
There could be a number of reasons for the difference in EDSS score outcome identified between EIT 
and ESC approaches in this study. While it is possible that compliance (time spent on treatment) may 
have been lower in those on moderate efficacy DMTs, the data points toward several other 
contributors. First, those individuals who embarked on an escalation approach but subsequently 
required escalation to a high-efficacy agent had a higher baseline ARR (1.2) than those who 
continued with moderate efficacy therapy (0.7). These data suggest that existing thresh-olds for 
using an EIT approach (eg, rapidly evolving severe MS) may be too high. Second, the majority of 
disability accumulation in the escalation group occurred while these individuals were receiving 
moderate-efficacy therapies, implying that contemporary methods of clinical and magnetic 
resonance imaging surveillance were insufficiently responsive to trigger escalation. Meanwhile, the 
reduction in relapse rate experienced after high-efficacy therapy appeared to be similarly great 
whether it was given as first-line or as escalation therapy, suggesting that the benefit of high-efficacy 
therapy on relapse rate does not diminish after a mean delay of 2.4 years. 
Limitations 
This study is subject to limitations that are common to population cohort data, such as a lack of 
uniformly acquired imaging or adverse event data compared with clinical trials. Various monitoring 
algorithms have been proposed to prompt escalation of DMT, 22-25 but none is universally accepted 
and some are not feasible in all real-world clinical settings.10 We feel that this cohort is likely to 
represent the manner in which the majority of contemporary cohorts in developed countries were 
managed during the period. The data have practical relevance and may also provide a measure of 
the translatability of clinical trial results into general clinical practice, where resources tend to be 
more limited. 
Conclusions 
Despite evidence from phase 3 trials that monoclonal antibodies are likely to have superior efficacy 
than more established DMTs,26,27 the widespread uptake of first-line, high-efficacy DMT has not 
emerged. Our study undermines the prevalent belief that an escalation approach represents a 
lower-risk strategy to MS treatment and suggests that in the real world, an escalation approach to 
DMT may be inadequate to prevent unfavorable long-term outcomes. These data should prompt a 
more detailed study of whether refined selection and escalation criteria could negate the long-term 
risk of disability accumulation observed in this escalation cohort. 
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